-

STEMCELL Technologies President and CEO Dr. Allen Eaves Appointed to the Order of Canada

VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies is proud to announce its President and CEO, Dr. Allen Eaves, has been appointed to the Order of Canada by Her Excellency the Right Honourable Mary Simon, the Governor General of Canada.

One of the nation’s highest forms of recognition, the Order of Canada recognizes people who make extraordinary contributions to Canadian society.

“Being appointed to the Order of Canada is an honour of a lifetime, and I am grateful for the countless colleagues, mentors, friends, and family members who supported me throughout my career,” Dr. Eaves said. “While I consider myself a physician-scientist and entrepreneur, I am also a proud Canadian at heart and feel incredibly fortunate to have had the opportunity to work in this country doing what I love: advancing science with the hope of creating a better world.”

Born in Ottawa and raised in Nova Scotia, Dr. Eaves obtained his undergraduate degree in biology from Acadia University, his medical degree from Dalhousie University and his PhD in medical biophysics from the University of Toronto. He specialized in internal medicine and medical oncology in Toronto and Vancouver following which he became a research scholar for what is now known as Michael Smith Health Research BC. In 1985, Dr. Eaves was appointed Head of Clinical Hematology at the University of British Columbia, the Vancouver General Hospital, and the BC Cancer Agency where he served for 18 years and focused on building one of Canada’s first and largest bone marrow transplant programs. He has served on many boards and committees for various medical and scholarly societies throughout his decades-long career and co-authored more than 200 articles in leading scientific journals.

In 1981, Dr. Eaves co-founded the Terry Fox Laboratory for Hematology/Oncology Research where he served as Director for 25 years. In 1993, he founded STEMCELL Technologies by mortgaging his home and has since grown it into Canada's largest biotechnology company with over 2000 employees who develop cutting-edge products and services for the global life sciences community.

“Over the years, Dr. Eaves has made enormous contributions to the advancement of science and has been at the forefront of the biotech industry here in Canada and around the world,” said Dr. Sharon Louis, Senior Vice President, Research and Development, STEMCELL. “Throughout his extraordinary career, he has also mentored many scientists, including myself, and continues to inspire all of us to meet high standards of quality and scientific rigour, while having lots of fun along the way.”

Recipients of the Order of Canada will be invited to accept their insignia at a ceremony to be held at a future date. Learn more about the recognition here.

About STEMCELL Technologies

STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.

Contacts

For more information and to arrange an interview, contact Ryan-Sang Lee, Senior Manager, Corporate Communications, STEMCELL Technologies: public.relations@stemcell.com

STEMCELL Technologies


Release Summary
STEMCELL Technologies is proud to announce its President and CEO, Dr. Allen Eaves, has been appointed to the Order of Canada.
Release Versions

Contacts

For more information and to arrange an interview, contact Ryan-Sang Lee, Senior Manager, Corporate Communications, STEMCELL Technologies: public.relations@stemcell.com

Social Media Profiles
More News From STEMCELL Technologies

STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries

VANCOUVER, British Columbia--(BUSINESS WIRE)--To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet this man...

STEMCELL Technologies Announces Acquisition of Cellular Highways

VANCOUVER, British Columbia & CAMBRIDGE, England--(BUSINESS WIRE)--STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile. The acquisition includes...

STEMCELL Launches Novel Cell-Engineering CellPore™ Transfection System

VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies has commercially launched the CellPore™ Transfection System, providing a groundbreaking new technology with the potential to advance cell engineering research and the development of novel cell therapies to cure diseases. The CellPore™ Transfection System represents a substantial leap forward for cell engineering researchers, offering a novel method—known as mechanoporation—for cargo delivery into mammalian cells. Unlike traditi...
Back to Newsroom